AVEO Pharmaceuticals, Inc. (AVEO)

– Industry veteran brings extensive clinical development experience to AVEO Oncology leadership team as Chief Medical Officer –

– Industry veteran brings extensive clinical development experience to AVEO Oncology leadership team as Chief Medical Officer –

BOSTON, Feb. 06, 2024 (GLOBE NEWSWIRE) -- AVEO Oncology , an LG Chem company (“AVEO”), today announced The Oncologist has published a post-hoc analysis of long-term progression free survival, overall survival and safety data from the Phase 3 TIVO-3 trial evaluating FOTIVDA® (tivozanib) in patients with relapsed or refractory (R/R) advanced renal cell carcinoma (RCC). In the publication, FOTIVDA demonstrated a consistent safety profile and a long-term survival benefit in patients who were alive and progression-free at 12 months, suggesting a durable clinical benefit and safety across age groups regardless of prior treatment.

BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”), an LG Chem company, today announced enrollment of the first patient in the FIERCE-HN trial, a global, multicenter, randomized, double-blind, placebo-controlled, phase 3 clinical trial evaluating ficlatuzumab in combination with ERBITUX® (cetuximab), an anti-EGFR antibody, in patients with human papillomavirus (HPV)-negative recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Ficlatuzumab is AVEO's investigational antibody that targets hepatocyte growth factor (HGF).

We present four biotech stocks, AVEO, CABA, VRNA and WVE, which despite the current volatile market, have provided more than twice the returns in 2022.

Here is how AVEO Pharmaceuticals (AVEO) and Merit Medical (MMSI) have performed compared to their sector so far this year.

AVEO Oncology (AVEO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Does AVEO Pharmaceuticals (AVEO) have what it takes to be a top stock pick for momentum investors? Let's find out.

AVEO (AVEO) delivered earnings and revenue surprises of 43.75% and 1.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AVEO (AVEO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AVEO Oncology's (AVEO) third-quarter earnings is expected to reflect strong Fotivda sales. The company is likely to beat the Zacks Consensus Estimate.

Here is how AVEO Pharmaceuticals (AVEO) and Akero Therapeutics, Inc. (AKRO) have performed compared to their sector so far this year.

LG Chem is buying AVEO Oncology for $566 million. These are the details.

Aveo Pharmaceuticals Inc (NASDAQ:AVEO) stock is soaring today, up 40.7% at $14.74 at last glance, after news that South Korean chemical company LG Chem plans to buy the biopharmaceutical name for $15 per share, or roughly $566 million, in an all-cash deal.

Aveo Oncology agreed to be acquired by Korea's LG Chem on Tuesday, and Aveo stock skyrocketed to a near two-year high on the news. The post Aveo Stock Continues Its Bullish Run After Snagging $566 Million LG Chem Buyout appeared first on Investor's Business Daily.

AVEO Oncology (NASDAQ: AVEO ) stock jumped 40% in premarket trading after LG Chem (OTCMKTS:LGCLF) said it would buy the company for $15/share in cash. The price implies a value of $566 million for AVEO.